1. ALLA AKTIER
  2. NYHETER
  3. NEOLA MEDICAL

Neola Medical

Nyheter Neola Medical Nyheter alla bolag

Neola Medical’s CEO shares spring milestones and strengthened shareholder base in 2025 investor letter

As 2025 unfolds, Neola Medical highlights key progress in clinical development and financing. The company has received approval from Swedish authorities to initiate its first clinical study on preterm born babies in Sweden and has completed a successful directed share issue of approximately SEK 20 million, strengthening its shareholder base with the addition of new institutional investors alongside existing shareholders.

“We have received approval from Swedish authorities to initiate our first clinical pilot study in Sweden, marking a major milestone as Neola® will be used for the first time on preterm born babies in neonatal intensive care. This achievement reflects years of development and our ability to navigate complex regulatory pathways. In parallel, we completed a successful directed share issue of approximately SEK 20 million, supported by new institutional investors, including Cicero Fonder and Adrigo Fonder, as well as existing shareholders, including Anmiro AB. Their participation complements our strong shareholder base and reflects long-term confidence in Neola Medical and our mission,” says CEO Hanna Sjöström.

Read more in the Investor letter spring 2025, attached to this press release and available on the company’s website www.neolamedical.com

For further information, contact:
Hanna Sjöström, CEO
e-mail: hanna.sjostrom@neolamedical.com

About Neola Medical
Neola Medical AB (publ) develops revolutionizing medical technology device for non-invasive continuous lung monitoring and real-time alerts of life-threatening lung complications of preterm born infants. Immediate detection of complications provides the possibility of early treatment, improved health care and healthier lives for preterm born infants. The patented cutting-edge technology is developed at Lund University in Sweden and based on a spectroscopic method that measures lung volume changes and oxygen gas concentration. Neola Medical is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to global health care. The company was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company’s Certified Adviser is FNCA Sweden AB.

Attachments
Neola Medical’s CEO shares spring milestones and strengthened shareholder base in 2025 investor letter
Neola Medical Investor Letter Spring 2025

Datum 2025-04-01, kl 07:45
Källa MFN
Bifogade filer
Neola Medical’s CEO shares spring milestones and strengthened shareholder base in 2025 investor letter
Neola Medical Investor Letter Spring 2025
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!